X.-Y. Wang et al. / Bioorg. Med. Chem. 14 (2006) 6745–6751
6749
NHCH), 2.89–2.79 (m, 2H, S–CH2–uracil), 2.73–2.65
(m, 2H, NCHCH2S), 1.38 (s, 9H, C(CH3)3); ESI-MS:
m/z = 344.4 [Mꢁ1]ꢁ; HRMS (ESI) calcd for
C13H19N3O6SNa [M+Na]+: m/z = 368.0887. Found:
368.0889.
1.10 mmol) and i-C4H9OCOCl (0.134 mL, 1.00 mmol)
were added at about ꢁ15 ꢁC. After 10 min, a solution
of 3Boc-cyclen (0.472 g, 1.00 mmol) in anhydrous
THF (30 mL) was poured into the reaction mixture.
The mixture was stirred for another 0.5 h at ꢁ15 ꢁC
and left overnight at room temperature. The mixture
was then evaporated under reduced pressure to remove
the solvent. The solid residue was dissolved in ethyl ace-
tate and washed with saturated NaHCO3, saturated
brine, and 2 N citric acid, the organic layer was dried
with anhydrous Na2SO4. After the solvent was evapo-
rated, the residue was purified by column chromatogra-
phy on silica gel (eluent: ethyl acetate/petroleum ether/
acetone = 1:1:1, v/v/v) to afford compounds 5 (0.615 g)
3.4. Preparation of compound 3
To a solution of N-tert-butyloxycarbonyl-S-thyminyl-L-
cysteine 2 (1.03 g, 3.00 mmol) in anhydrous tetrahydro-
furan (THF, 40 mL) was added N-methyl morphine
(NMM) (0.390 mL, 3.30 mmol) and i-C4H9OCOCl
(0.402 mL, 3.00 mmol) sequentially at about ꢁ15 ꢁC.
After stirring for 10 min, a solution of L-phenylalanine
methyl ester (3.30 mmol) and NMM (0.390 mL,
3.30 mmol) in anhydrous THF (60 mL) was poured into
the reaction mixture. The mixture was stirred for anoth-
er 0.5 h at ꢁ15 ꢁC and left overnight at room tempera-
ture. After the solvent was evaporated under reduced
pressure, the solid residue was dissolved in ethyl acetate
and washed with saturated NaHCO3, saturated brine
and 2 N citric acid, the organic layer was dried with
anhydrous Na2SO4. After the solvent was removed,
the residue was purified by recrystallization from
acetone and ethyl ether. Compound 3 (1.366 g) was
obtained as a white powder. Yield: 90%, mp 210–
1
as a white solid. Yield: 65%, mp 141–143 ꢁC; H NMR
(400 MHz, CDCl3) d: 10.28 (s, 1H, uracil-1-NH), 9.88
(s, 1H, uracil-3-NH), 7.75 (s, 1H, CONH), 7.57 (s, 1H,
uracil-6-CH), 7.37–7.24 (m, 5H, Ph-H), 5.59 (s, 1H,
OCONH), 5.10–5.05 (m, 1H, CHCON), 4.54–4.50 (m,
1H, Boc-NHCH), 3.57–3.02 (m, 18H, Ph-CH2, cyclen–
CH2), 2.81–2.79 (m, 2H, S–CH2–uracil), 2.73–2.68 (m,
2H, NCHCH2S), 1.50–1.41 (m, 36H, Boc-H); ESI-MS:
m/z = 970.1 [M+Na]+.
3.7. Preparation of compound 6
1
212 ꢁC; H NMR (400 MHz, DMSO) d: 11.17 (s, 1H,
To a solution of compound 5 (0.500 mmol) in ethanol
(10 mL), 47.5% aqueous HBr (5 mL) was added drop-
wise. After being stirred at room temperature overnight,
the reaction mixture was concentrated under reduced
pressure to give the crude product, which was crystal-
lized from ethanol/24% aqueous HBr to afford
compound 6 (0.333 g) as a white powder. Yield: 77%,
uracil-1-NH), 10.85 (d, 1H, J = 4.0 Hz, uracil-3-NH),
8.29 (d, 1H, J = 7.6 Hz, CONH), 7.40 (d, 1H,
J = 5.6 Hz, uracil-6-CH), 7.28–7.18 (m, 5H, Ph-H),
6.92 (d, 1H, J = 8.4 Hz, OCONH), 4.49–4.44 (m, 1H,
CHCOOCH3), 4.15–4.09 (m, 1H, Boc-NHCH), 3.57 (s,
3H, OCH3), 3.30–3.27 (m, 2H, Ph-CH2), 3.05–2.91 (m,
2H, S–CH2–uracil), 2.66–2.49 (m, 2H, NCHCH2S),
1.37 (s, 9H, C(CH3)3); ESI-MS: m/z = 505.1 [Mꢁ1]ꢁ.
1
mp 239–241 ꢁC; H NMR (400 MHz, D2O) d: 7.63 (s,
1H, uracil-6-CH), 7.35–7.22 (m, 5H, Ph-H), 4.47–4.44
(m, 1H, CHCON), 4.30–4.24 (m, 1H, NH2CH), 3.65–
3.06 (m, 18H, Ph-CH2, cyclen–CH2), 3.01–2.95 (m,
2H, S–CH2–uracil), 2.92–2.87 (m, 2H, NCHCH2S);
ESI-MS: m/z = 547.6 [Mꢁ4HBr+1]+.
3.5. Preparation of compound 4
2N Aqueous sodium hydroxide (5 mL, 10 mmol) was
added dropwise to a suspension of compound 3
(2.00 mmol) in methanol (20 mL) at 0 ꢁC. The mixture
was stirred for 2 h at room temperature and the pH
was adjusted to 7 with 1 N HCl. After removing most
of the methanol, the pH was adjusted to about 2. The
mixture was then extracted with ethyl acetate (3·
30 mL) and the organic layer was dried with anhydrous
Na2SO4. After the solvent was evaporated under
reduced pressure, compound 4 (0.964 g) was obtained
3.8. Preparation of PNA–cyclen metal complexes (7)
To an aqueous solution (5 mL) of compound 6 (0.304 g,
0.350 mmol), an aqueous solution (5 mL) of
Zn(ClO4)2Æ6H2O (0.134 g, 0.360 mmol) was added
slowly. The pH of the solution was adjusted to 8–9
with 1 N NaOH. After being stirred overnight, the
reaction mixture was concentrated under reduced pres-
sure. The obtained residue was crystallized from water
to afford zinc(II) complex 7a (0.215 g) as a white sol-
1
as a white solid. Yield: 98%, mp 211–212 ꢁC; H NMR
(400 MHz, DMSO) d: 12.80 (s, 1H, COOH), 11.17 (s,
1H, uracil-1-NH), 10.84 (d, 1H, J = 5.6 Hz, uracil-3-
NH), 8.05 (d, 1H, J = 7.6 Hz, CONH), 7.46 (d, 1H,
J = 8.4 Hz, uracil-6-CH), 7.39–7.19 (m, 5H, Ph-H),
6.94 (d, 1H, J = 8.4 Hz, OCONH), 4.47–4.40 (m, 1H,
CHCOOH), 4.16–4.12 (m, 1H, Boc-NHCH), 3.31–3.27
(m, 2H, Ph-CH2), 2.56–2.54 (m, 2H, S–CH2–uracil),
2.52–2.45 (m, 2H, NCHCH2S), 1.37 (s, 9H, C(CH3)3);
ESI-MS: m/z = 515.5 [M+Na]+.
1
id. Yield: 76%, mp 391–393 ꢁC; H NMR (400 MHz,
D2O) d: 7.50–7.46 (m, 1H, uracil-6-CH), 7.13–7.05
(m, 5H, Ph-H), 4.18–4.15 (m, 1H, CHCON), 4.10–
4.06 (m, 1H, NH2CH), 3.49–2.88 (m, 18H, Ph-CH2,
cyclen–CH2), 2.82–2.75 (m, 2H, S–CH2–uracil), 2.70–
2.66 (m, 2H, NCHCH2S); ESI-MS: m/z = 609.6
[Mꢁ2ClO4]+.
To an aqueous solution (5 mL) of compound 6 (0.304 g,
0.350 mmol), 1 N NaOH was added to adjust pH 8–9.
Cu(NO3)2 (0.068 g, 0.360 mmol) was then added. The
reaction mixture was stirred overnight and blue precipi-
tate was formed. The reaction mixture was concentrated
3.6. Preparation of compound 5
To a solution of compound 4 (1.00 mmol) in anhydrous
THF (20 mL), N-methyl morphine (NMM) (0.130 mL,